ecDNA (extrachromosomal DNA): What is it, its mode of inheritance and its impact on cancer

Extrachromosomal DNA (ecDNA) plays an increasingly recognized role in the development, progression, and treatment resistance of cancer.

1. What is extrachromosomal DNA?

Extrachromosomal DNA (ecDNA) refers to the DNA found outside chromosomes. Unlike the linear chromosomes in the nucleus, ecDNA is typically circular and can replicate independently. It often contains gene sequences, such as oncogenes, which are genes that can drive cancer when overexpressed or mutated. In normal cells, ecDNA may include mitochondrial DNA, which has a separate genome and aids in cellular energy production. However, in cancer cells, ecDNA often carries multiple copies of oncogenes, enabling them to bypass cellular controls, replicate extensively, and contribute to rapid tumor growth and drug resistance.

In cancer, ecDNA behaves differently from chromosomal DNA by replicating independently and randomly segregating into daughter cells during division. This random distribution introduces variability, which can help tumors adapt and resist treatment. Recent studies have shown that ecDNA can form “hubs” in the cell nucleus where multiple ecDNAs cluster, amplifying their transcriptional activity and enhancing the aggressive behavior of the cancer cells

2. Mode of Inheritance of ecDNA:

- **Non-Mendelian Inheritance:** Unlike chromosomal DNA, which follows Mendelian inheritance patterns (segregating equally during cell division), ecDNA is inherited in a non-Mendelian fashion. This means ecDNA distribution to daughter cells is often irregular, leading to heterogeneous copies of ecDNA in each cell.
- **Random Segregation:** During cell division, ecDNA is randomly segregated, so some cells may inherit more ecDNA copies than others. This unequal distribution can contribute to genetic heterogeneity within the tumor, thus facilitating cancer evolution.
- **Self-Replication:** ecDNA can replicate independently of the cell cycle. Thus, ecDNA copies can multiply quickly, enabling the amplification of oncogenes on ecDNA and further accelerating tumor growth.

3. Mechanisms of ecDNA in Cancer:

ecDNA plays a significant role in cancer development and progression through several mechanisms:

- **Oncogene Amplification:** ecDNA harbors amplified copies of oncogenes (e.g., MYC, EGFR). Since ecDNA is not bound by chromosomal regulatory mechanisms, these genes can be highly expressed, leading to rapid cell proliferation and more aggressive tumor behavior.
- **Genetic Heterogeneity:** The random inheritance pattern and self-replication of ecDNA contribute to genetic diversity in cancer cells. This heterogeneity makes the tumor more adaptable and resistant to standard treatments, as some cells may acquire survival advantages.
- **Transcriptional Activity**: ecDNA is more open and accessible than chromosomal DNA, resulting in higher transcriptional activity. This means that the genes on ecDNA are more actively transcribed, further driving cancer progression.
- **Therapeutic Resistance:** Cells with ecDNA can adapt quickly to therapies. This is because ecDNA can rapidly change and adapt, making it harder for therapies to target and eliminate cancer cells. For example, if a targeted drug blocks a specific pathway, ecDNA with amplified resistance genes can help bypass the block, promoting survival and recurrence.
- **Epigenetic Effects**: ecDNA lacks the typical regulatory environment of chromosomal DNA, resulting in gene expression that is not controlled by conventional epigenetic mechanisms. This lack of regulation leads to overexpression of oncogenes and can also impact nearby genes, further contributing to cancer aggressiveness.

4. Implications for Cancer Treatment

- **Targeting ecDNA**: Therapeutic strategies are being explored to target ecDNA specifically, either by inhibiting its replication or preventing its expression of oncogenes.
- **EcDNA as a Biomarker**: Detection of ecDNA in tumors or blood samples may serve as a biomarker for prognosis and treatment resistance, helping guide personalized treatment approaches.

In summary, ecDNA contributes to cancer by amplifying oncogenes, increasing tumor heterogeneity, and facilitating therapy resistance. Its unique mode of inheritance and replication makes it a critical target for future cancer treatments.

References:

1. Turner, K. M., Deshpande, V., Beyter, D., et al. (2017). "Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity." *Nature*, 543(7643), 122–125.
2. Verhaak, R. G. W., & Bafna, V. (2019). "The problem with oncogene amplifications on extrachromosomal DNA." *Nature Reviews Cancer*, 19(5), 283–284.
3. Koche, R. P., Rodriguez-Fos, E., Helmsauer, K., et al. (2020). "Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma." *Nature Genetics*, 52(1), 29–34.
4. Nathanson, D. A., Gini, B., & Mottahedeh, J. (2020). "Targeted Therapy Resistance Mediated by Dynamic Regulation of Extrachromosomal DNA Amplification." *Cell*, 183(6), 1733-1748.e15.
5. Yi, E., Osuna de la Peña, D., Kanagal-Shamanna, R., & Luthra, R. (2022). "Extrachromosomal DNA in cancer: Emerging trends and future directions." *Seminars in Cancer Biology*, 83, 184–198.
6. Kim, H., Nguyen, N. P., Turner, K., Wu, S., & Gujar, A. D. (2020). "Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers." *Nature Genetics*, 52(9), 891–897.
7. Chris Bailey, et al., Origins and impact of extrachromosomal DNA. Nature | Vol 635 | 7 November 2024.
8. King L. Hung, et al., Coordinated inheritance of ecDNAs in cancer cells. Nature | Vol 635 | 7 November 2024.
9. Jun Tang, et al., Enhancing transcription–replication conflict targets ecDNA-positive cancers. Nature | Vol 635 | 7 November 2024.